Coronavirus Update: US FDA Panel To Review J&J’s Vaccine On 26 February
Plus: Daiichi Signs Japan Deal With AZ
Executive Summary
Johnson & Johnson's vaccine produced a significantly lower efficacy readout than the mRNA frontrunners, but its success in preventing severe disease with one dose will be a gamechanger, if approved.
You may also be interested in...
Pfizer And Moderna Reap Rewards Of Expanded US And EU Deals
The two rival mRNA vaccines are proving attractive in the face of new variants, and could dominate once SARS-CoV2 enters the ‘endemic’ stage.
Japan Approves First Coronavirus Vaccine But Hurdles Ahead?
Japanese authorities have issued their first approval for a coronavirus vaccine, to Pfizer/BioNTech’s mRNA product Comirnaty, but public vaccine hesitancy and logistics challenges could be hurdles to achieving high administration rates and effective herd immunity.
EU Backs Down In Row Over AstraZeneca Vaccine Supplies
The European Commission has averted all-out conflict with AstraZeneca and the UK government, with good news from J&J and Pfizer/BioNTech easing supply concerns.